Status:
WITHDRAWN
Study of the Effects of Iron on Lung Blood Pressure at High Altitude
Lead Sponsor:
University of Oxford
Collaborating Sponsors:
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Conditions:
Hypertension, Pulmonary
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Body iron levels may be important in determining how the blood pressure in the lungs changes in response to low oxygen levels. At high altitude, where oxygen levels are low, some patients develop elev...
Detailed Description
Pulmonary hypertensive disorders frequently complicate hypoxic lung disease and worsen patient survival. Hypoxia-induced pulmonary hypertension is also a major cause of morbidity at high altitude. Hy...
Eligibility Criteria
Inclusion
- High altitude natives, currently resident at high altitude
- Pulmonary hypertension (mean pulmonary artery pressure \> 25 mmHg)
- Pulmonary artery systolic pressure measurable using Doppler echocardiography
Exclusion
- Clinical evidence or history of major co-morbidity
- Recent changes to relevant medications, or taking iron/vitamin supplements
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00960921
Last Update
May 15 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Molecular Biology and Medicine
Bishkek, Kyrgyzstan, 720040